A randomized, double-blind, placebo-controlled phase II study of CERC-301 for the adjunctive treatment of major depressive disorder
Latest Information Update: 21 Nov 2016
At a glance
- Drugs Rislenemdaz (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 08 Nov 2016 Top-line results from this trial are expected in November 2016, according to a Cerecor Inc. media release.
- 01 Oct 2016 New trial record